All In MedTech

Device Trial Radar · NCT03232333

MIRODERM H2H DFU Study

Effectiveness of MIRODERM® Biologic Wound Matrix in the Treatment of Hard-to-Heal Diabetic Foot Ulcers

Last checked: Nov 20, 2026Latest source record: Oct 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

53

Actual

Start

Jul 21, 2017

Primary completion

Sep 20, 2018

Study completion Sep 20, 2018

Sponsor

Lead sponsor
Miromatrix Medical Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jul 28, 2017

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

This study will assess the ability of MIRODERM to heal difficult diabetic foot ulcers within 12 weeks of treatment.

Conditions

  • Diabetic Foot Ulcer

Interventions

  • Biologic wound graftDevice

    Diabetic foot ulcer will be treated by grafting with MIRODERM Biologic Wound Matrix

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of ParticipantsTime frame: 12 weeks

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • ILD Research

    Carlsbad, California

8 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.